Cargando…

High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination

COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated im...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadyrova, Irina, Yegorov, Sergey, Negmetzhanov, Baurzhan, Kolesnikova, Yevgeniya, Kolesnichenko, Svetlana, Korshukov, Ilya, Akhmaltdinova, Lyudmila, Vazenmiller, Dmitriy, Stupina, Yelena, Kabildina, Naylya, Ashimova, Assem, Raimbekova, Aigul, Turmukhambetova, Anar, Miller, Matthew S., Hortelano, Gonzalo, Babenko, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/
https://www.ncbi.nlm.nih.gov/pubmed/35895743
http://dx.doi.org/10.1371/journal.pone.0272008
_version_ 1784757749253406720
author Kadyrova, Irina
Yegorov, Sergey
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Akhmaltdinova, Lyudmila
Vazenmiller, Dmitriy
Stupina, Yelena
Kabildina, Naylya
Ashimova, Assem
Raimbekova, Aigul
Turmukhambetova, Anar
Miller, Matthew S.
Hortelano, Gonzalo
Babenko, Dmitriy
author_facet Kadyrova, Irina
Yegorov, Sergey
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Akhmaltdinova, Lyudmila
Vazenmiller, Dmitriy
Stupina, Yelena
Kabildina, Naylya
Ashimova, Assem
Raimbekova, Aigul
Turmukhambetova, Anar
Miller, Matthew S.
Hortelano, Gonzalo
Babenko, Dmitriy
author_sort Kadyrova, Irina
collection PubMed
description COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response.
format Online
Article
Text
id pubmed-9328563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93285632022-07-28 High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination Kadyrova, Irina Yegorov, Sergey Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Akhmaltdinova, Lyudmila Vazenmiller, Dmitriy Stupina, Yelena Kabildina, Naylya Ashimova, Assem Raimbekova, Aigul Turmukhambetova, Anar Miller, Matthew S. Hortelano, Gonzalo Babenko, Dmitriy PLoS One Research Article COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response. Public Library of Science 2022-07-27 /pmc/articles/PMC9328563/ /pubmed/35895743 http://dx.doi.org/10.1371/journal.pone.0272008 Text en © 2022 Kadyrova et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kadyrova, Irina
Yegorov, Sergey
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Akhmaltdinova, Lyudmila
Vazenmiller, Dmitriy
Stupina, Yelena
Kabildina, Naylya
Ashimova, Assem
Raimbekova, Aigul
Turmukhambetova, Anar
Miller, Matthew S.
Hortelano, Gonzalo
Babenko, Dmitriy
High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title_full High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title_fullStr High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title_full_unstemmed High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title_short High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
title_sort high sars-cov-2 seroprevalence in karaganda, kazakhstan before the launch of covid-19 vaccination
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/
https://www.ncbi.nlm.nih.gov/pubmed/35895743
http://dx.doi.org/10.1371/journal.pone.0272008
work_keys_str_mv AT kadyrovairina highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT yegorovsergey highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT negmetzhanovbaurzhan highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT kolesnikovayevgeniya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT kolesnichenkosvetlana highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT korshukovilya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT akhmaltdinovalyudmila highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT vazenmillerdmitriy highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT stupinayelena highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT kabildinanaylya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT ashimovaassem highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT raimbekovaaigul highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT turmukhambetovaanar highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT millermatthews highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT hortelanogonzalo highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination
AT babenkodmitriy highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination